The combination of mTORC1 inhibitor Everolimus with EGFR-TKIs has clinical efficacy in TKIs-resistant NSCLC cell lines [3], but the subsequent clinical trials show limited effect of combination therapy on unselected NSCLC patients [4]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.